Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.36 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | ESRRB | O95718 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374750 | 1.00 | PIN1 (0.40) | PIN1LMNARHEBCA1CA2 | |
| SCHEMBL26606901 | 0.86 | KMT2A (0.39) | PIN1RHEBCA1CA2VCAM1 | |
| SCHEMBL29375294 | 0.83 | PIN1 (0.38) | PIN1RHEBCA1CA2KDM1A | |
| SCHEMBL22401515 | 0.83 | PIN1 (0.38) | PIN1RHEBCA1CA2KDM1A | |
| SCHEMBL4785913 | 0.83 | LMNA (0.62) | PIN1LMNARHEBKDM1ACYP11B2 | |
| SCHEMBL30540334 | 0.80 | NT5E (0.60) | PIN1LMNAKDM4EHIF1ACYP11B2 | |
| SCHEMBL22401516 | 0.79 | TRPV4 (0.43) | PIN1LMNAHIF1ANT5E | |
| SCHEMBL29374256 | 0.79 | TRPV4 (0.43) | PIN1LMNAHIF1ANT5E | |
| SCHEMBL7505331 | 0.75 | PIN1 (0.40) | PIN1LMNARHEBCA1CA2 | |
| SCHEMBL730084 | 0.75 | PDE5A (0.49) | VCAM1CCNCCDK8CDKN1ACDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708568-B1 | COMPOUND CAPABLE OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD, AND MEDICAL USE THEREOF | HEFEI INDUSTRIAL PHARMACEUTICAL INST CO LTD (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11161860-B2 | Compound having effects of inhibiting phosphodiesterase 4, preparation method thereof and pharmaceutical use thereof | Hefei Industrial Pharmaceutical Institute Co., Ltd (CN) | 2021-11-02 | — | — | US | disclosed |
| US-20210179640-A1 | COMPOUND HAVING EFFECTS OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HEFEI INDUSTRIAL PHARMACEUTICAL INSTITUTE CO., LTD. (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3708568-A1 | COMPOUND CAPABLE OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD, AND MEDICAL USE THEREOF | Hefei Industrial Pharmaceutical Institute Co., Ltd (CN) | 2020-09-16 | — | — | EP | disclosed |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-5801180-A | ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | EISAI CO., LTD. (JP) | 1998-09-01 | — | — | US | disclosed |
| US-5693652-A | Benzimidazoles for ischemic heart conditions | EISAI CO., LTD. (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | JUN, CHUK, RELA | PIN1 964/4885LMNA 4382/4885RHEB 3158/4885 |
| US-20210179640-A1 | COMPOUND HAVING EFFECTS OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | PDE4A, PDE3B, PDE4B | PIN1 2012/4885LMNA 2986/4885RHEB 3411/4885 |
| US-11161860-B2 | Compound having effects of inhibiting phosphodiesterase 4, preparation method thereof and pharmaceutical use thereof | PDE4A, PDE3B, PDE4B | PIN1 2012/4885LMNA 2986/4885RHEB 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.